CV outcomes with medicines to control glycemia: highlights from recently completed trials

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Effects of empaglifozin on kidney outcomes after acute MI
Effects of empaglifozin on kidney outcomes after acute MI
ESC Congress 2024
Effects of empaglifozin on kidney outcomes after acute MI
- Deepak Bhatt, MD
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
The effect of icosapent ethyl on CV events in metabolic syndrome
Diabetes
The effect of icosapent ethyl on CV events in metabolic syndrome
- Michael Miller, MD
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
Kidney Disease
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
- Carolyn Lam, MD, PhD
- Maria Luiza Caramori, MD, PhD
- Ana Maria Cebrián-Cuenca, MD, PhD
- Pam R. Taub, MD, FACC, FASPC